Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Issues Statement after 3rd Death Potentially Tied to Lecanemab Reported
December 26, 2022
- Shionogi JV, Shanghai Pharma Ink Xocova Import Pact in China
December 26, 2022
- Sanofi Launches Cablivi in Japan for Acquired TTP
December 26, 2022
- Opdivo-Chemo Combo Fails in Asian Adjuvant Study for Gastric Cancer
December 26, 2022
- Yescarta Gets Second-Line Nod for Large B-Cell Lymphoma in Japan
December 26, 2022
- PeptiDream, US Merck Strike Deal on PDC Development
December 23, 2022
- Kaken Subsidiary Hits PII Goal for Vascular Malformation Drug
December 23, 2022
- Janssen Labor Union to Hold 1st Bargaining Session as Early as Jan. 11
December 23, 2022
- Takeda, Mitsubishi, IIF to Operate Shonan iPark under New Joint Firm
December 22, 2022
- Genmab Files Epcoritamab for Large B-Cell Lymphoma in Japan
December 22, 2022
- Padcev/Keytruda Combo Accepted for FDA Review in Bladder Cancer
December 22, 2022
- Livtencity Misses PIII Goal in 1st Line Use for HSCT CMV Infection
December 21, 2022
- Eisai to Divest US Fycompa Rights to Catalyst, Focus on Alzheimer’s R&D
December 21, 2022
- Nippon Shinyaku’s JAK2 Inhibitor Earns Orphan Designation in US
December 21, 2022
- Daiichi Sankyo’s Blood Cancer Drug Ezharmia Now Available
December 21, 2022
- Breyanzi Now Approved in Japan for 2nd-Line Large B-Cell Lymphoma: BMS
December 21, 2022
- Chugai CEO Questions Off-Year Price Cuts for On-Patent Meds
December 21, 2022
- Janssen Japan Employees Form Labor Union to Counter Closing of Positions
December 21, 2022
- Chugai Eyes Submission of Oral GLP-1 Agent in 2025-2026: R&D Briefing
December 20, 2022
- Kissei Won’t Change 2025 Targets Despite Linzagolix Setback, Decide US Plan by March
December 20, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…